Influence of a low dose of amphetamine on vesicular monoamine transporter binding: A PET (+)[11C]DTBZ study in humans |
| |
| Authors: | Isabelle Boileau Sylvain Houle Pablo M. Rusjan Yoshiaki Furukawa Diana Wilkins Junchao Tong Peter Selby Alan A. Wilson Stephen J. Kish |
| |
| Affiliation: | 1. Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada;2. Vivian M. Rakoff PET Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada;3. Addictions Program, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada;4. Movement Disorders Research Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada;5. Center for Human Toxicology, University of Utah, Salt Lake City, Utah |
| |
| Abstract: | We previously reported increased binding of (+)[11C]DTBZ (dihydrotetrabenazine), the vesicular monoamine transporter (VMAT2) positron emission tomography (PET) radioligand, in striatum of some methamphetamine users. This finding might be explained by stimulant‐induced vesicular DA depletion resulting in decreased DA (+)[11C]DTBZ competition at VMAT2. In a prospective PET study, we now find that administration of an acute oral dose of amphetamine (0.4 mg/kg) to humans does not cause increased striatal (+)[11C]DTBZ binding but a slight 5% decrease. Our data suggest that a low amphetamine dose is unlikely to cause sufficient DA depletion to detect increased (+)[11C]DTBZ binding and that a higher dose might be required. Synapse 64:417–420, 2010. © 2010 Wiley‐Liss, Inc. |
| |
| Keywords: | vesicular monoamine transporter II positron emission tomography dihydrotetrabenazine amphetamine dopamine |
|
|
